Stockscreener 앱 받기
0.389
9.27%
0.033
시장 영업 전:
.37
-0.019
-4.88%
전일 마감가:
$0.356
열려 있는:
$0.339
하루 거래량:
1.59M
Relative Volume:
1.27
시가총액:
$15.81M
수익:
$656.60K
순이익/손실:
$-16.79M
주가수익비율:
-0.3621
EPS:
-1.0743
순현금흐름:
$-11.12M
1주 성능:
+12.59%
1개월 성능:
+2.94%
6개월 성능:
-24.48%
1년 성능:
-76.42%
1일 변동 폭
$0.3376
$0.394
1주일 범위
$0.29
$0.394
52주 변동 폭
$0.2382
$2.60
Scienture Holdings Inc Stock (SCNX) Company Profile
명칭
Scienture Holdings Inc
전화
(800) 261 0281
주소
20 AUSTIN BLVD., COMMACK
Compare SCNX vs HITI, PETS, POM, WGRX
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SCNX
Scienture Holdings Inc
|
0.389 | 14.46M | 656.60K | -16.79M | -11.12M | -1.0743 |
HITI
High Tide Inc
|
2.16 | 191.56M | 486.49M | -33.29M | 10.86M | -0.3627 |
PETS
Petmed Express Inc
|
1.95 | 40.82M | 182.67M | -64.87M | -22.92M | -3.1193 |
POM
Pomdoctor Ltd Adr
|
1.44 | 10.59M | 0 | 0 | 0 | 0.00 |
WGRX
Wellgistics Health Inc
|
2.93 | 7.31M | 14.03M | -76.59M | -13.73M | -41.45 |
Scienture Holdings Inc 주식(SCNX)의 최신 뉴스
Scienture Holdings stock jumps over 20% pre-market: Here's why - MSN
Scienture Holdings Company Profile & Introduction - Moomoo
Maxim Group Maintains Scienture Holdings(SCNX.US) With Buy Rating, Maintains Target Price $1.5 - Moomoo
Scienture Holdings Stock Jumps Over 20% Pre-Market: Here's Why - Sahm
Scienture Holdings (SCNX) Registration filing Summary - Quartr
The trading volume of these stocks is deviating from the norm in today's session. - ChartMill
Scienture Holdings, Inc. Completes Manufacturing of Commercial Launch Inventory and Begins Shipments of Rezenopy Nasal Spray 10 Mg to U.S. Pharmaceutical Wholesalers - marketscreener.com
Scienture (SCNX) Prepares for Rezonopy Nasal Spray Launch - GuruFocus
Scienture completes manufacturing for naloxone spray launch By Investing.com - Investing.com Canada
Scienture completes manufacturing for naloxone spray launch - Investing.com
SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers - marketscreener.com
SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY (Naloxone Hydrochloride) to Wholesalers - Moomoo
Scienture Holdings (SCNX) Slips 4% as Stock Tests Key Support Near $0.31Daily Profile - dars.gov.et
Scienture secures $11M debt financing for product launches - Investing.com
SCNX Q1 2026 Earnings: Significant EPS Beat Amid Pre-Revenue Stage as Scienture Outperforms Analyst ExpectationsEPS Surprise History - dars.gov.et
Price to sales forward of Scienture Holdings, Inc. – NASDAQ:SCNX - TradingView
Price to book forward of Scienture Holdings, Inc. – NASDAQ:SCNX - TradingView
Price to earnings forward of Scienture Holdings, Inc. – NASDAQ:SCNX - TradingView
Scienture Holdings, Inc. Actuals & Estimates (NASDAQ:SCNX) - TradingView
SCNX Q1 2026 Earnings: EPS Surprise of 64.35% Amid Revenue Silence; Stock Declines 1.42%Profit Recovery Report - dars.gov.et
SCNX Forecast — Price Target — Prediction for 2027 - TradingView
Scienture Holdings Inc. (SCNX) Q1 2026 Earnings: Narrower-than-Expected Loss Fails to Lift Shares - dars.gov.et
Scienture Holdings Inc (SCNX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Scienture Holdings Inc (SCNX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Scienture stock rises after adding 12.5M covered lives for Arbli - Investing.com Nigeria
Scienture stock rises after adding 12.5M covered lives for Arbli By Investing.com - Investing.com Australia
Scienture (SCNX) Advances Commercialization of Arbli - GuruFocus
Scienture expands payor coverage for Arbli by 12.5M lives - Investing.com
SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide - marketscreener.com
Scienture Holdings Inc (SCNX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Scienture Holdings Inc (SCNX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Scienture Holdings Inc (SCNX) Institutional Confidence - TradingKey
Scienture Holdings Inc (SCNX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Scienture Holdings Inc (SCNX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Scienture Holdings Inc (SCNX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Scienture Holdings Inc (SCNX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Analysts Conflicted on These Healthcare Names: Moderna (MRNA) and Scienture Holdings (SCNX) - The Globe and Mail
Scienture Holdings Inc. (SCNX) Q1 2026 Earnings: EPS Surprise of 64.35% Drives Stock RallyDividend Growth Analysis - dars.gov.et
SCNX Q1 2026 Earnings: Significant EPS Beat Signals Cost-Cutting ProgressRevenue Miss Report - DonanımHaber
SCNX Q1 2026 Earnings: Loss Narrower Than Expected as Stock Declines 4.66%Dividend Earnings Report - newsline.com
Exclusive: Scienture expands coverage for opioid overdose treatment ahead of commercial launch - MSN
SCNX Q1 2026 Earnings: Narrower-Than-Expected Loss Boosts SentimentEarnings Weakness Phase - newsline.com
Scienture Holdings (SCNX) Investor Relations, Earnings Summary & Outlook - Quartr
Scienture Holdings (SCNX) Q3 2025 earnings summary - Quartr
Scienture Holdings Inc. (SCNX) Rallies 6.43% to $0.38, Nears Key ResistanceRSI Oversold Picks - newsline.com
Scienture Holdings Inc at Small Cap Showcase & WTR Insights Conference Transcript - GuruFocus
SCNX Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive MomentumCore Business Growth - newsline.com
Scienture’s naloxone nasal spray added to national health plan By Investing.com - Investing.com South Africa
Scienture Holdings, Inc. Secures Formulary Coverage for REZENOPYTM with Large National Health Plan and Expands Commercial Team - marketscreener.com
Scienture’s naloxone nasal spray added to national health plan - Investing.com UK
SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team - The Manila Times
Scienture Holdings Inc (SCNX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.41%
0.92%
자본화:
|
볼륨(24시간):